Zaccardi F, Webb DR, Yates T, Davies MJ. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective. Postgrad Med J. 2016;92:63–9.
Kahn S. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3–19.
Ufuoma C, Ngozi JC, Kester AD, Godwin YD. Prevalence and risk factors of microalbuminuria among type 2 diabetes mellitus: a hospital-based study from, Warri, Nigeria. Sahel Med J. 2016;19:16.
Kumar KP, Ghosh S, Canovatchel W, Garodia N, Rajashekar S. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21:196.
Zghebi SS, Steinke DT, Carr MJ, Rutter MK, Emsley RA, Ashcroft DM. Examining trends in type 2 diabetes incidence, prevalence and mortality in the UK between 2004 and 2014. Diabetes Obes Metab. 2017;19:1537–45.
Zhou T, Meng X, Che H, Shen N, Xiao D, Song X, et al. Regulation of insulin resistance by multiple MiRNAs via targeting the GLUT4 signalling pathway. Cell Physiol Biochem. 2016;38:2063–78.
Mackenzie RW, Elliott BT. Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes. 2014;7:55.
Eriksson J, Koranyi L, Bourey R, Schalin-Jäntti C, Widen E, Mueckler M, et al. Insulin resistance in type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle. Diabetologia. 1992;35:143–7.
García-Cáceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, et al. Astrocytic insulin signaling couples brain glucose uptake with nutrient availability. Cell. 2016;166:867–80.
Buck MD, O’Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med. 2015;212:1345–60.
Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol. 2012;12:749.
Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med. 1986;163:1037–50.
He Q. Yang Q-c, Zhou Q, Zhu H, Niu W-y, Feng J, et al. effects of varying degrees of intermittent hypoxia on proinflammatory cytokines and adipokines in rats and 3T3-L1 adipocytes. PLoS One. 2014;9:e86326.
Lüscher BP, Marini C, Joerger-Messerli MS, Huang X, Hediger MA, Albrecht C, et al. Placental glucose transporter (GLUT)-1 is down-regulated in preeclampsia. Placenta. 2017;55:94–9.
Macintyre AN, Gerriets VA, Nichols AG, Michalek RD, Rudolph MC, Deoliveira D, et al. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 2014;20:61–72.
Yamagata AS, Mansur RB, Rizzo LB, Rosenstock T, McIntyre RS, Brietzke E. Selfish brain and selfish immune system interplay: a theoretical framework for metabolic comorbidities of mood disorders. Neurosci Biobehav Rev. 2017;72:43–9.
MacIver NJ, Jacobs SR, Wieman HL, Wofford JA, Coloff JL, Rathmell JC. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol. 2008;84:949–57.
Yang Z, Yang J, Liu W, Wu L, Xing L, Wang Y, et al. T2D@ ZJU: a knowledgebase integrating heterogeneous connections associated with type 2 diabetes mellitus. Database. 2013;2013.
Gopinath K, Jayakumararaj R, Karthikeyan M. DAPD: a knowledgebase for diabetes associated proteins. IEEE/ACM Trans Comput Biol Bioinform. 2015;12:604–10.
Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery Consortium, et al. In Silico approach for predicting toxicity of peptides and proteins. Plos One. 2013;8(9):e73957.
Islam SMA, Sajed T, Kearney CM, Baker EJ. PredSTP: a highly accurate SVM based model to predict sequential cystine stabilized peptides. BMC Bioinform. 2015;16:210.
UniProt CT. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 2018;46:2699.
Kayatekin C, Amasino A, Gaglia G, Flannick J, Bonner JM, Fanning S, et al. Translocon Declogger Ste24 protects against IAPP oligomer-induced Proteotoxicity. Cell. 2018;173:62–73.
Gasteiger E, Hoogland C, Gattiker A, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The proteomics protocols handbook. Totowa: Springer; 2005. p. 571–607.
Yu CS, Lin CJ, Hwang JK. Predicting subcellular localization of proteins for gram-negative bacteria by support vector machines based on n-peptide compositions. Protein Sci. 2004;13:1402–6.
Van Zundert G, Rodrigues J, Trellet M, Schmitz C, Kastritis P, Karaca E, et al. The HADDOCK2. 2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2016;428:720–5.
Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005;57:33–41.
Bui H-H, Sidney J, Li W, Fusseder N, Sette A. Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines. BMC Bioinform. 2007;8:361.
Camproux A-C, Gautier R, Tuffery P. A hidden markov model derived structural alphabet for proteins. J Mol Biol. 2004;339:591–605.
Hornung V, Ablasser A, Charrel-Dennis M, Bauernfeind F, Horvath G, Caffrey DR, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458:514.
Chen JY, Pandey R, Nguyen TM. HAPPI-2: a comprehensive and high-quality map of human annotated and predicted protein interactions. BMC Genomics. 2017;18:182.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein–protein association networks, made broadly accessible. Nucleic Acids Res. 2016;45:D362–D8.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform. 2008;9:40.
Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010;5:725.
Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER suite: protein structure and function prediction. Nat Methods. 2015;12:7.
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF chimera—a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605–12.
Pathan M, Keerthikumar S, Chisanga D, Alessandro R, Ang C-S, Askenase P, et al. A novel community driven software for functional enrichment analysis of extracellular vesicles data. J Extracell. 2017;6:1321455.
Colovos C, Yeates TO. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993;2:1511–9.
Benkert P, Tosatto SC, Schomburg D. QMEAN: a comprehensive scoring function for model quality assessment. Proteins: Structure Funct Bioinform. 2008;71:261–77.
Studer G, Biasini M, Schwede T. Assessing the local structural quality of transmembrane protein models using statistical potentials (QMEANBrane). Bioinformatics. 2014;30:i505–i11.
Lovell SC, Davis IW, Arendall WB, De Bakker PI, Word JM, Prisant MG, et al. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. Proteins: Structure Funct Bioinform. 2003;50:437–50.
Bhattacharya D, Nowotny J, Cao R, Cheng J. 3Drefine: an interactive web server for efficient protein structure refinement. Nucleic Acids Res. 2016;44:W406–W9.
Bhattacharya D, Cheng J. i3Drefine software for protein 3D structure refinement and its assessment in CASP10. PLoS One. 2013;8:e69648.
Bhattacharya D, Cheng J. 3Drefine: consistent protein structure refinement by optimizing hydrogen bonding network and atomic-level energy minimization. Proteins: Structure Funct Bioinform. 2013;81:119–31.
Cheng J, Randall AZ, Sweredoski MJ, Baldi P. SCRATCH: a protein structure and structural feature prediction server. Nucleic Acids Res. 2005;33:W72–W6.
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:4.
Doytchinova IA, Flower DR. Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. Vaccine. 2007;25:856–66.
Doytchinova IA, Flower DR. Bioinformatic approach for identifying parasite and fungal candidate subunit vaccines. Open Vaccine J. 2008;1:4.
Bjellqvist B, Hughes GJ, Pasquali C, Paquet N, Ravier F, Sanchez JC, et al. The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences. Electrophoresis. 1993;14:1023–31.
Nezafat N, Ghasemi Y, Javadi G, Khoshnoud MJ, Omidinia E. A novel multi-epitope peptide vaccine against cancer: an in silico approach. J Theor Biol. 2014;349:121–34.
Cnop M, Welsh N, Jonas J-C, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54:S97–S107.
Spohn G, Schori C, Keller I, Sladko K, Sina C, Guler R, et al. Preclinical efficacy and safety of an anti-IL-1β vaccine for the treatment of type 2 diabetes. Mol Ther-Meth Clin D. 2014;1:140–8.
Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.
Zhang Y, Yu X-L, Zha J, Mao L-Z, Chai J-Q, Liu R-T. Therapeutic vaccine against IL-1β improved glucose control in a mouse model of type 2 diabetes. Life Sci. 2018;192:68–74.
Herder C, Dalmas E, Böni-Schnetzler M, Donath MY. The IL-1 pathway in type 2 diabetes and cardiovascular complications. Trends Endocrinol Metab. 2015;26:551–63.
Ludvigsson J, Faresjö M, Hjorth M, Axelsson S, Chéramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008;359:1909–20.
Cook DP, Gysemans C, Mathieu C. Prospects of a type 1 diabetes vaccine. Expert Opin Biol Ther. 2017;17:403–6.
Wofford JA, Wieman HL, Jacobs SR, Zhao Y, Rathmell JC. IL-7 promotes Glut1 trafficking and glucose uptake via STAT5-mediated activation of Akt to support T-cell survival. Blood. 2008;111:2101–11.
Islam S, Mir AR, Arfat MY, Alam K, Ali A. Studies on glycoxidatively modified human IgG: implications in immuno-pathology of type 2 diabetes mellitus. Int J Biol Macromol. 2017;104:19–29.
Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, et al. Metabolic reprogramming of macrophages glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem. 2014;289:7884–96.
Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007;18:1437–46.
Shikhman AR, Brinson DC, Valbracht J, Lotz MK. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol. 2001;167:7001–8.
Bédard S, Marcotte B, Marette A. Cytokines modulate glucose transport in skeletal muscle by inducing the expression of inducible nitric oxide synthase. Biochem J. 1997;325:487–93.
Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor α and blood cytokine production in type 2 diabetes. Life Sci. 2000;67:291–300.
Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769–77.
Stephens JM, Carter BZ, Pekala P, Malter J. Tumor necrosis factor alpha-induced glucose transporter (GLUT-1) mRNA stabilization in 3T3-L1 preadipocytes. Regulation by the adenosine-uridine binding factor. J Biol Chem. 1992;267:8336–41.
King BC, Esguerra JL, Golec E, Eliasson L, Kemper C, Blom AM. CD46 activation regulates miR-150–mediated control of GLUT1 expression and cytokine secretion in human CD4+ T cells. J Immunol. 2016;196:1636–45.
Dhanda SK, Usmani SS, Agrawal P, Nagpal G, Gautam A, Raghava GPS. Novel in silico tools for designing peptide-based subunit vaccines and Immunotherapeutics. Brief Bioinformat. 2017;2017(18):467–78.
Lu K, Su B, Meng X. Recent advances in the development of vaccines for diabetes, hypertension, and atherosclerosis. J Diabetes Res. 2018;24:1638462.
Monteiro MP. Obesity vaccines. Hum Vaccin Immunother. 2014;10:887–95.
Zha J, Chi XW, Yu XL, et al. Interleukin-1β-targeted vaccine improves glucose control and β-cell function in a diabetic KK-ay mouse model. PLoS One. 2016;11:e0154298.
Cavelti-Weder C, Timper K, Seelig E, et al. Development of an interleukin-1β vaccine in patients with type 2 diabetes. Molecular Ther. 2016;24:1003–12.
Cornell S. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes. J Clin Pharm Ther. 2012;37:510–24.
Pang Z, Nakagami H, Osako MK, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceed Nat Aca Sci Uni Stat Amer. 2014;111:E1256–63.
Hasan M, Islam MS, Chakraborty S, Mustafa AH, Azim KF, Joy ZF, et al. Contriving a chimeric polyvalent vaccine to prevent infections caused by herpes simplex virus (Type-1 and Type-2): an exploratory immunoinformatic approach. J Biomol Struct Dyn. 2019;12:1–18.